financetom
Business
financetom
/
Business
/
Valaris Insider Sold Shares Worth $1,449,994, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Valaris Insider Sold Shares Worth $1,449,994, According to a Recent SEC Filing
Sep 30, 2024 10:02 PM

05:01 PM EDT, 09/30/2024 (MT Newswires) -- Matthew Lyne, Senior Vice President and Chief Commercial Officer, on September 30, 2024, sold 26,000 shares in Valaris ( VAL ) for $1,449,994. Following the Form 4 filing with the SEC, Lyne has control over a total of 24,388 shares of the company, with 24,388 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/314808/000031480824000146/xslF345X05/wk-form4_1727729419.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MUFG Expects SNB to Hold Rates as Swiss Franc Strength Persists
MUFG Expects SNB to Hold Rates as Swiss Franc Strength Persists
Sep 22, 2025
06:47 AM EDT, 09/22/2025 (MT Newswires) -- The Swiss franc (CHF) has held firm over the past month even as global investor risk sentiment improved and equity markets hit fresh records, MUFG said. USD/CHF briefly touched a year-to-date low of 0.7829 on Sept. 17, while EUR/CHF slid toward the bottom of its recent 0.9300-0.9400 range, the bank wrote in a...
Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion
Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion
Sep 22, 2025
Sept 22 (Reuters) - Pfizer ( PFE ) said on Monday it would acquire weight-loss drug developer Metsera ( MTSR ) for up to $4.9 billion to secure its position in the lucrative obesity treatment market. ...
Johnson & Johnson Says Tremfya Gets FDA Approval for Subcutaneous Induction in Adults With Ulcerative Colitis
Johnson & Johnson Says Tremfya Gets FDA Approval for Subcutaneous Induction in Adults With Ulcerative Colitis
Sep 22, 2025
06:46 AM EDT, 09/22/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday the US Food and Drug Administration approved a subcutaneous induction regimen of Tremfya to treat moderately to severely active ulcerative colitis in adult patients. Commercially insured patients may be eligible to receive their first induction treatment in as little as 24 hours through Tremfya withMe,...
Exclusive-Bezos-backed renewables alliance targets $7.5 billion for developing countries
Exclusive-Bezos-backed renewables alliance targets $7.5 billion for developing countries
Sep 22, 2025
LONDON (Reuters) -An alliance that installs renewable energy in developing countries wants to invest around $7.5 billion during its next five-year plan, executives told Reuters, and is seeking more philanthropic partners as richer nations cut government aid. The Global Energy Alliance for People and Planet, launched at global climate talks in 2021, has helped 30-plus countries to enhance electricity grids,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved